Category: Movement disorders

VMAT2 inhibitors function by depleting monoamine neurotransmitters like dopamine in the brain, thereby controlling involuntary movements. This class of drugs, including tetrabenazine, deutetrabenazine, and valbenazine, is used to manage specific movement disorders like tardive dyskinesia and Huntington's chorea.

Propranolol is an FDA-approved treatment option for essential tremor, proven to reduce tremor severity in a majority of patients. The question of “Can propranolol help with tremors?” is often asked, as it is a widely prescribed medication for controlling involuntary shaking.

While uncommon, abnormal involuntary movements like dystonia are a recognized potential side effect of carbamazepine [1.6.1]. Understanding this link is crucial, so the question remains: **can carbamazepine cause dystonia**, and what should patients know?

Affecting approximately 10 million Americans, essential tremor is the most common movement disorder, but it is not the only cause of tremors. Finding the right treatment requires an accurate diagnosis, as the answer to 'What is the best medication to help with tremors?' depends heavily on the underlying condition.

About 70-90% of people with Parkinson's disease (PD) experience a tremor at some point [1.9.4]. A key question for patients and clinicians is, does amantadine help with tremors? This article examines its role, mechanism, and efficacy for various tremor types.

Levodopa-induced dyskinesia (LID) affects approximately 30% of Parkinson's disease patients after about four years of treatment [1.7.3, 1.7.4]. For many, a key question is: how long does amantadine benefit on dyskinesia of severe Parkinson's disease last?

While there is currently no single cure or FDA-approved treatment for the most common forms of cerebellar ataxia, particularly hereditary types, there are medications and therapies available to manage symptoms. The primary goal of treatment is to improve a patient's quality of life by addressing the specific symptoms and underlying cause where possible.

According to a French pharmacovigilance database study, drug-induced myoclonus accounted for 0.2% of all adverse drug reaction reports [1.3.2]. Understanding **what drugs cause jerking** is crucial for patients and healthcare providers to recognize and manage this potential side effect, known as myoclonus.

First approved by the FDA in 2017 for tardive dyskinesia, Ingrezza was the first medication developed specifically for this condition. This makes many wonder: What type of med is Ingrezza? It is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, a class of drugs that regulates dopamine signaling in the brain.

Pharmacological inhibition of the vesicular monoamine transporter 2 (VMAT2) has been shown to cause depressive-like symptoms in humans, a finding that helped establish the monoamine-deficiency hypothesis of depression. Today, understanding **what happens if VMAT2 is inhibited** is crucial for treating specific neurological disorders by regulating neurotransmitter levels in the brain.